Immatics Stock (NASDAQ:IMTX), Trade Ideas

Immatics

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Equities

News

Small Cap

Markets

Movers

General

IMTX

Immatics N.V. (NASDAQ: IMTX) shares are trading higher after the company announced 

Why Immatics Shares Are Rising Today

Penny Stocks

Short Ideas

Intraday Update

Trading Ideas

BHVN

NAUT

VALN

ZURA

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Top 5 Health Care Stocks That May Crash This Month

Biotech

Health Care

Immatics N.V. (NASDAQ: IMTX) shares are shooting higher today after it revealed an interim clinical data update for 11 patients with recurrent and/or refractory solid cancers treated with ACTengine IMA203 TCR-T monotherapy in the ongoing Phase 1b 

What&#39;s Going On With Immatics Shares Today

Immatics NV

Amazon.com Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) has launched a new grocery delivery subscription benefit&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38373619/amazon-introduces-low-cost-grocery-delivery-subscription-for-prime-members-and-customers-using-ebt" rel="noreferrer noopener">available&nbsp;to Prime members and customers using EBT.</a>
The facility will be available in more than 3,500 cities and towns across the U.S. At $9.99 per month for Prime members, the subscription provides unlimited grocery delivery on orders over $35 from Amazon Fresh, Whole Foods Market along with local grocery and specialty retailers on Amazon.com.
Customers who hold a registered EBT card avail grocery subscription benefits without a Prime membership for $4.99 per month. The Subscription includes one-hour delivery windows at no extra cost, unlimited 30-minute pickup on orders of any size.
&#8220;This new grocery subscription benefit provides even more value and savings on delivery fees for customers who regularly order groceries from Amazon Fresh, Whole Foods Market, and the variety of local grocery and specialty retailers on Amazon.com,&#8221; said Tony Hoggett, senior vice president of worldwide grocery stores at Amazon.
The service aims to streamline grocery shopping, offering one-hour delivery windows where available and priority access to Recurring Reservations for weekly orders.
Following successful pilots in select cities, Amazon&#8217;s grocery subscription garnered high satisfaction rates among users. Over 85% of respondents expressed extreme or very high satisfaction with the free delivery benefit, citing savings on fees and enhanced convenience as key factors for continued subscription.
Amazon stock gained 69% in the last 12 months. Investors can gain exposure to the stock via&nbsp;SPDR Select Sector Fund&nbsp;–&nbsp;Consumer Discretionary&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) and&nbsp;Vanguard Consumer Discretion ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VCR#NYSE">VCR</a>).
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38376999/amazon-ends-drone-deliveries-in-lockeford-sets-eye-on-new-arizona-site-for-expansion" rel="noreferrer noopener">Amazon Ends Drone Deliveries in Lockeford, Sets Eye on New Arizona Site for Expansion</a>
Price Action: AMZN shares closed higher by 1.30% at $179.544 on Tuesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

AMZN

Select Sector SPDR-Consumer Discretionary

Enhanced Convenience: Amazon Launches New Affordable Grocery Delivery Subscription

Needham analyst Chris Pierce reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Hold.

Reiteration

Analyst Ratings

TSLA

Needham Reiterates Hold on Tesla

Needham analyst Mayank Tandon maintains CoStar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) with a Buy and raises the price target from $90 to $107.

Price Target

CSGP

Needham Maintains Buy on CoStar Gr, Raises Price Target to $107

Needham analyst Quinn Bolton reiterates Vicor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) with a Hold.

VICR

Needham Reiterates Hold on Vicor

B. Riley Securities analyst Jeff Lick upgrades Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) from Sell to Neutral and lowers the price target from $12 to $7.

Upgrades

PLCE

B. Riley Securities Upgrades Children's Place to Neutral, Lowers Price Target to $7

&nbsp;Immutep Limited ((ASX: IMM, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) (&ldquo;Immutep&rdquo; or &ldquo;the Company&rdquo;), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) &nbsp;Phase &nbsp;IIb &nbsp;trial &nbsp;evaluating &nbsp;eftilagimod &nbsp;alpha &nbsp;(efti) in combination with MSD&rsquo;s anti-PD-1 &nbsp;therapy KEYTRUDA&reg; &nbsp;(pembrolizumab) &nbsp;as &nbsp;first-line treatment of &nbsp;recurrent/metastatic &nbsp;head &nbsp;and &nbsp;neck &nbsp;squamous &nbsp;cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.

IMMP

Immutep Announced Tuesday, Data  From Efti In  Combination  With Keytruda In  First  Line Head  And  Neck  Squamous  Cell  Carcinoma Patients Who Do Not Express PD-L1 Shows A Preliminary 26.9% Response Rate, The Primary Endpoint Of The Study

Pivotal Research analyst Jeffrey Wlodarczak upgrades Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) from Hold to Buy and lowers the price target from $5.05 to $4.9.

SIRI

Pivotal Research Upgrades Sirius XM Holdings to Buy, Lowers Price Target to $4.9

<a href="https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-novel-treatment-babies" title="https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-novel-treatment-babies">https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-novel-treatment-babies</a>

Large Cap

Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety

Elon Musk has escalated his conflict with the Australian government, advocating for the incarceration of a senator and voicing criticism of Australia&#8217;s gun laws. This follows a court directive to remove a violent video from his social media platform, X.
What Happened: On Tuesday, an X user posted a clip of Australian Sen. Jacqui Lambie who deleted her X account and encouraged other politicians to follow suit. Lambie criticized Musk for his lack of social conscience and suggested he should be jailed.
"…quite frankly, the power that that man has because of that platform that he's on, it's got to stop. It has absolutely got to stop. But leaving that out for our kids to see, for people that were family and friends out there and just letting that run on there, once again, that bloke has no conscience. He's an absolute friggin disgrace, and there's nothing else to say about Elon Musk," Lambie said. 
Musk responded to the post, saying, &#8220;Absolutely. She is an enemy of the people of Australia.&#8221;
Musk&#8217;s disagreement with Australian authorities heightened after a federal court demanded his social media platform, X, to temporarily stop displaying a video showing a knife assault on an Assyrian bishop, This order led Musk to accuse Australia&#8217;s leaders of internet censorship.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Absolutely. She is an enemy of the people of Australia.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1782823597381414933?ref_src=twsrc%5Etfw">April 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/24/04/38357333/elon-musk-reacts-to-tucker-carlson-saying-theres-ton-of-evidence-that-aliens-live-among-us-with-6000?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts To Tucker Carlson Saying There&#8217;s &#8216;Ton Of Evidence&#8217; That Aliens Live Among Us: &#8216;With 6000 Satellites Orbiting Earth, I Think I Would Know&#8217;</a>
Why It Matters: This incident follows a <a href="https://www.benzinga.com/government/23/10/35257873/elon-musks-x-faces-386k-penalty-in-australia-for-dodging-child-abuse-probe">penalty of $386,000</a> that was imposed on X by the Australian regulator last year for inadequate compliance with a child abuse prevention investigation.
Musk extended his criticism to Australia&#8217;s 1996 gun buy-back and registration scheme, endorsing a post that alleged the scheme was designed to prevent resistance against its &#8220;fascist government&#8221;.
Australia&#8217;s Home Affairs Minister <a href="https://www.benzinga.com/news/24/04/38368734/elon-musk-hits-back-at-australias-leader-amid-row-over-removal-of-violent-video-from-x-does-the-pm-t">Clare O&#8217;Neill accused social media companies</a> of inciting &#8220;civil division, social unrest&#8221; and criticized Musk for legally defending the right to display alleged terrorist content on his platform. 
A hearing to decide the permanence of the takedown order is scheduled for May 10.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38348301/bitcoin-halving-elon-musks-dogecoin-tweet-solanas-rise-and-more-this-week-in-cryptocurrenc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Halving, Elon Musk&#8217;s Dogecoin Tweet, Solana&#8217;s Rise And More: This Week In Cryptocurrency</a>
Photo courtesy: Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Social Media

Global

Tech

'Enemy Of People:' Elon Musk Slams Australian Senator After She Calls Tesla CEO 'Absolute Friggin Disgrace'

Pivotal Research analyst Jeffrey Wlodarczak maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $390 to $400.

SPOT

Pivotal Research Maintains Buy on Spotify Technology, Raises Price Target to $400

Needham analyst Joshua Reilly reiterates Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Buy and maintains $400 price target.

AXON

Needham Reiterates Buy on Axon Enterprise, Maintains $400 Price Target

Piper Sandler analyst Brad Milsaps downgrades Independent Bank Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBTX#NASDAQ">IBTX</a>) from Neutral to Underweight and lowers the price target from $48 to $38.

Downgrades

IBTX

Piper Sandler Downgrades Independent Bank Gr to Underweight, Lowers Price Target to $38

Needham analyst Ryan Koontz maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and lowers the price target from $50 to $45.

CALX

Needham Maintains Buy on Calix, Lowers Price Target to $45

Piper Sandler analyst Brian Mullan initiates coverage on Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) with a Neutral rating and announces Price Target of $114.

Initiation

KRUS

Piper Sandler Initiates Coverage On Kura Sushi USA with Neutral Rating, Announces Price Target of $114

Piper Sandler analyst Stephen Scouten upgrades SmartFinancial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBK#NYSE">SMBK</a>) from Neutral to Overweight and raises the price target from $25 to $26.

SMBK

Piper Sandler Upgrades SmartFinancial to Overweight, Raises Price Target to $26

Needham analyst Ami Fadia maintains Day One Biopharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) with a Buy and raises the price target from $30 to $33.

DAWN

Needham Maintains Buy on Day One Biopharmaceutical, Raises Price Target to $33

Mizuho analyst James Lee upgrades Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Neutral to Buy and raises the price target from $150 to $200.

ABNB

Mizuho Upgrades Airbnb to Buy, Raises Price Target to $200

Outlook&nbsp;for the&nbsp;Fourth Quarter&nbsp;of the Fiscal Year 2024
New Oriental expects total net revenues in the&nbsp;fourth quarter&nbsp;of the fiscal year 2024 (March 1, 2024&nbsp;to&nbsp;May 31, 2024) to be in the range of&nbsp;US$1,101.5 million&nbsp;to&nbsp;US$1,127.3 million, representing year over year increase in the range of&nbsp;28%&nbsp;to&nbsp;31%.
The projected increase of revenue in our functional currency Renminbi is expected to be in the range of&nbsp;34%&nbsp;to&nbsp;37%&nbsp;for the&nbsp;fourth quarter&nbsp;of the fiscal year 2024.

Guidance

New Oriental Education & Technology Group

New Oriental Education Expects Q4 Revenue of $1.102B-$1.127B Vs $1.099B Est

New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) reported quarterly earnings of $0.63 per share which missed the analyst consensus estimate of $0.79 by 20.25 percent. This is a 12.5 percent increase over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $1.207 billion which beat the analyst consensus estimate of $1.105 billion by 9.30 percent. This is a 60.09 percent increase over sales of $754.153 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

New Oriental Education Q3 2024 Adj EPS $0.63 Misses $0.79 Estimate, Sales $1.207B Beat $1.105B Estimate

Lloyds Banking Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYG#NYSE">LYG</a>) reported quarterly earnings of $0.22 per share. This is a 98.2 percent increase over earnings of $0.11 per share from the same period last year. The company reported $4.04 billion in sales this quarter. This is a 30.62 percent decrease over sales of $5.82 billion the same period last year.

Lloyds Banking Group Q1 EPS $0.22 Up From $0.11 YoY, Sales $4.04B Down From $5.82B YoY

The 81 rating InvestorsObserver gives to Immatics NV (IMTX)  stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 95 percent of stocks in the Biotechnology industry, IMTXâ€&#x2122;s 81 overall rating means the stock scores better than 81 percent of all stocks. IMTX has an Overall Score of 81.

Is Immatics NV (IMTX) a Good Choice in Biotechnology Tuesday?

Immatics NV (IMTX) is near the top in its sector according to InvestorsObserver.IMTX gets an overall rating of 73. That means it scores higher than 73% of stocks.Immatics NV gets a 93 rank in the Healthcare sector. Healthcare is number 1 out of 11 sectors. IMTX has an Overall Score of 73. Find out what this means to you an

Will Immatics NV (IMTX) Outperform the Rest of the Stocks in the Healthcare Sector?

Immatics reports FY results

Immatics N.V. (IMTX) has released an update. Immatics N.V. has reported significant progress in its clinical trials, including a 50% confirmed obje...

Immatics N.V. Showcases Clinical Strides and Fiscal Health

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Immatics (NASDAQ:<a href="https://investorplace.com/stock-quotes/imtx-stock-quote/">IMTX</a>) just reported results for the fourth quarter of 2023.<ul><li>Immatics reported earnings per share of -32 cents. This was above the analyst estimate for EPS of -35 cents.</li><li>The company reported revenue of $17.14 million.</li><li>This was 4.69% better than the analyst estimate for revenue of $16.37 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/imtx-stock-earnings-immatics-for-q4-of-2023/">IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023

Immatics NV (IMTX) stock is down 6.00% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator. Immatics NV has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IMTX!See Full IMTX ReportWhat is Stock Sentiment?Sentiment uses short term technic

Immatics NV (IMTX) Stock: What Does the Chart Say Friday?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immatics (IMTX – Research Report), Vor Biopharma (VO...

Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)

Immatics NV (IMTX) stock is up 58.60% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives IMTX stock a score of  70 out of a possible 100. That rank is  influenced by a long-term technical score of 72. IMTX's rank also includes a s

Immatics NV (IMTX) Stock Is Lower By -2.74% This Week: Buy, Hold, or Sell?

Immatics NV (IMTX) is around the top of the Biotechnology industry according to InvestorsObserver. IMTX received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Immatics NV also achieved a score of 72 in the Biotechnology industry, putting it above 72 percent of Biotechnology stock

Is Immatics NV (IMTX) a Leader in the Biotechnology Industry?

Immatics (IMTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 27. Analyst Graig Suvannavejh fro...

Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships

JAZZ

Contracts

Press Releases

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Management

Levicept Appoints Eliot Forster as CEO

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Immatics Announces Proposed Public Offering

Immatics Announces Pricing of $175 Million Public Offering

Immatics Announces Full Year 2023 Financial Results and Corporate Update

COYA

FSTX

IMCR

MRNA

REPL

Abivax

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Deciphera Pharmaceuticals, Inc. - Common Stock

Deciphera Pharmaceuticals

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Immunome

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd. - Class A Common Stock

Kiniksa Pharmaceuticals

MiMedx Group

Macrogenics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MannKind

Nurix Therapeutics

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Spyre Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

Zentalis Pharmaceuticals, Inc. - common stock